// App-Quantinova.ai

POS1052 (2021) : PSORIATIC ARTHRITIS AND OBESITY IMPACT DRUG PERSISTENCE IN USTEKINUMAB-TREATED PATIENTS WITH PSORIASIS IN THE BRITISH ASSOCIATION OF DERMATOLOGISTS BIOLOGIC AND IMMUNOMODULATORS REGISTER (BADBIR): A 10-YEAR FOLLOW-UP STUDY

Researchers

Presenter

  • A. Ogdie

Principal Investigators

  • W. Tillett

  • P. Gorecki

Medical Centers

  • University of Pennsylvania, Perelman School of Medicine, Department of Dermatology, Philadelphia, United States of America

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • Janssen Real World Evidence, HEMAR EMEA, High Wycombe, United Kingdom

  • Janssen, Medical Affairs, High Wycombe, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

  • Dermatology

  • Endocrine/metabolic Diseases (ME)

Disease

  • Psoriatic arthritis

  • Psoriasis

  • Obesity

Biomarkers

  • N/A

Drug/Treatment

  • Ustekinumab

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved